Literature DB >> 21114649

Preserved endocrine function in a pancreas transplant recipient with pancreatic panniculitis and antibody-mediated rejection.

M Prikis1, D Norman, S Rayhill, A Olyaei, M Troxell, A Mittalhenkle.   

Abstract

Pancreas transplantation is an effective treatment option for patients with complicated diabetes mellitus. Pancreas allograft recipients are followed with laboratory markers such as serum amylase, lipase and glucose levels. Hyperglycemia may indicate severe acute rejection and has recently been associated with antibody-mediated (humoral) rejection. In this report, we describe a unique case of a pancreas-after-kidney (PAK) transplant recipient with the rare presentation of pancreatic panniculitis, biopsy-proven severe acute cellular and antibody-mediated pancreas allograft rejection and surprisingly well-preserved endocrine function despite treatment with high dose steroids. We discuss the clinicopathologic features of antibody-mediated pancreas rejection, including the importance of correlating pancreas allograft biopsy, C4d staining and donor specific antibodies, to diagnose antibody-mediated rejection and initiate the correct treatment. ©2010 The Authors Journal compilation©2010 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21114649     DOI: 10.1111/j.1600-6143.2010.03332.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  2 in total

1.  Pancreatic panniculitis in a pancreas-kidney transplant patient resolved after immunosuppression increase: Case report and review of literature.

Authors:  Mara Beveridge; Susan Pei; Maria M Tsoukas
Journal:  JAAD Case Rep       Date:  2015-04-11

Review 2.  Pancreatic panniculitis in a patient with pancreatic-type acinar cell carcinoma of the liver--case report and review of literature.

Authors:  Sebastian Zundler; Ramona Erber; Abbas Agaimy; Arndt Hartmann; Franklin Kiesewetter; Deike Strobel; Markus F Neurath; Dane Wildner
Journal:  BMC Cancer       Date:  2016-02-20       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.